Ejlertsen Bent, Gerdes Anne-Marie A
Rigshospitalet, Finsencentret, Onkologisk Klinik, København Ø.
Ugeskr Laeger. 2007 Sep 3;169(36):2972-5.
In general, the treatment of early breast cancer is guided by the results from large randomised trials. The same does not apply to patients who carry BRCA1/2 mutations. The selection of loco-regional therapies might change according to BRCA1/2 mutation status. In order to reduce the risk of secondary breast and ovarian cancer, these patients may also be offered prophylactic oophorectomy. The possible impact of BRCA1/2 mutations on the efficacy of medical therapies has recently attained much interest, alongside the development of targeted therapies against BRCA1/2 associated cancers.
一般来说，早期乳腺癌的治疗是由大型随机试验的结果来指导的。但这并不适用于携带BRCA1/2基因突变的患者。局部区域治疗的选择可能会根据BRCA1/2基因突变状态而改变。为了降低继发乳腺癌和卵巢癌的风险，也可以为这些患者提供预防性卵巢切除术。近年来，随着针对BRCA1/2相关癌症的靶向治疗的发展，BRCA1/2基因突变对药物治疗疗效的可能影响备受关注。
